Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …

Protein aggregation has been recognized as one of the major challenges in the
development and commercialization of successful protein-based drug products because of …

In antibody light chain (AL) amyloidosis, overproduced light chain (LC) fragments
accumulate as fibrils in organs and tissues of patients. In vitro, AL fibril formation is a slow …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

Light chain (AL) amyloidosis is a devastating, complex, and incurable protein misfolding
disease. It is characterized by an abnormal proliferation of plasma cells (fully differentiated B …

Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-
cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC) …

Light chain (LC) amyloidosis (AL amyloidosis) appears to be caused by the misfolding, or
misfolding and aggregation of an antibody LC or fragment thereof and is fatal if untreated …

In Ig light-chain (LC) amyloidosis (AL), the unique antibody LC protein that is secreted by
monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to …

In systemic light chain amyloidosis, an overexpressed antibody light chain (LC) forms fibrils
which deposit in organs and cause their failure. While it is well-established that mutations in …

Light chain amyloidosis (AL), the most common systemic amyloidosis, is caused by the
overproduction and the aggregation of monoclonal immunoglobulin light chains (LC) in …